New combo vaccine targets flu, RSV, and more in early trial
NCT ID NCT06850051
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety and immune response of new vaccines that combine protection against flu, RSV, hMPV, and PIV3 in healthy adults aged 18 to 49. Participants received a single shot of one of several vaccine formulas. The goal was to see if these combination vaccines are safe and trigger a strong immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emeritus Research
Camberwell, Victoria, 3124, Australia
-
Griffith University
Southport, Queensland, 4215, Australia
-
Paratus Clinical
Blacktown, New South Wales, 2148, Australia
-
Paratus Clinical
Herston, Queensland, 4006, Australia
-
University of Sunshine Coast Clinical Trials
Morayfield, Queensland, 4506, Australia
-
University of Sunshine Coast Clinical Trials
South Brisbane, Queensland, 4101, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults